Evidence map›Paper›PMID 42627231›Full record

Trial reportJournal of virology2026

Factors impacting protective immunity conferred by vaccination with adeno-associated virus-like particles displaying human papillomavirus L2 residues 17-36.

Jade Alvarez, Pola Olczak, Hua-Ling Tsai, Jasmine Terrell, Margaret Wong, Hannah Tsingine, Vikrant Palande, Jeanette Prangsgaard, Emma Huus, Martin Műller and 2 more

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jade AlvarezDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Pola OlczakDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Hua-Ling TsaiDepartment of Biostatistics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Jasmine TerrellDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Margaret WongDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Hannah TsingineDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Vikrant PalandeDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Jeanette Prangsgaard2A Pharma ApS, Aalborg, Denmark.
Emma Huus2A Pharma ApS, Aalborg, Denmark.
Martin MűllerDeutsches Krebsforschungszentrum, Heidelberg, Germany.
John Dirk Vestergaard Nieland2A Pharma ApS, Aalborg, Denmark.
Richard B S RodenDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-2506-0195

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI WARNER KING HUH, TZYY-CHOOU WU · 2003 to 2026
$53.5M
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer ImmunotherapyR01CA237067 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2019 to 2023
$2.9M
2A Pharma ABCharles T. Bauer Charitable TrustCommonwealth Foundation for Cancer Research FoundationNCI NIH HHS P30 CA006973NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA237067NIH HHS P30CA006973NIH HHS P50CA098252NIH HHS R01CA237067
6 · The paper itself

Abstract

A phase I study was conducted in 20 healthy subjects with 20 µg adeno-associated virus 2 (AAV2)-like particles displaying L2 residues 17-36 of both human papillomavirus (HPV) type 16 and HPV31 (AAVLP-HPV) or placebo. AAVLP-HPV vaccination was well tolerated and induced a modest L2-specific serum antibody titer that neutralizes HPV16, HPV31, and HPV5

Indexed as

Capsid ProteinsDependovirusOncogene Proteins, ViralPapillomavirus InfectionsPapillomavirus VaccinesVaccines, Virus-Like ParticleAdultAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHuman papillomavirus 16Human papillomavirus 31HumansMiceVaccinationAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsL2 protein, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus VaccinesVaccines, Virus-Like ParticleAAV2Adeno-associated virusHPVhuman papillomavirusL2neutralizing antibodyprophylactic vaccine

Identifiers

PMID42627231
PMCPMC13595945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.